Renal Artery DenervatIon Using Radial accesS in Uncontrolled HyperTensioN

Non-inferiority, prospective, multi-center, international, post-market, randomized (1:1) clinical trial. 90 patients with uncontrolled hypertension treated with 2 to 5 antihypertensive drugs including one angiotensin receptor blocker (ARB) or angiotensin-converting enzyme Inhibitor (ACE-I) in combination with one diuretic or calcium channel blocker will be randomized in a 1:1 ratio to the radial access renal denervation group (intervention) or the femoral access renal denervation group (control). Around 12 sites in 3 European countries (France, Germany and Switzerland) are planned to enroll 90 patients. For patients with a contraindication for the TransFemoral Access (major femoral disease, bilateral femoral vascular prosthesis, extreme obesity), a register is also carried out in parallel with the study. The inclusion and exclusion criteria will be the same except the fact that patients have to be eligible for TransFemoral access, endpoints and data collected will be the same. All patients will be followed per standard of care practice and follow-up visits are scheduled at 3 months (follow-up time window +14 days) and 6 months (follow-up time window +30 days). Estimated duration of inclusions: 27 months. Total estimated duration of study: 38 months.